Opinion of the Transparency Council – doxazosinum (1 mg, 2 mg)

At its meeting on 29 July 2024, the Transparency Council adopted opinion No. 117/2024 on the on the inclusion in reimbursement of medicines containing the active substance doxazosinum for indications for use or dosage or route of administration different from those specified in the summary of product characteristics, i.e. chronic kidney disease in children under 18 years of age; neurogenic bladder dysfunction in children under 18 years of age; non-neurogenic bladder dysfunction in children under 18 years of age

Publication on the list of opinions on active substances for off-label indications >>